Research program

The AGIR laboratory is interested in the development of new anti-infective molecules, possessing specific antimicrobial properties and/or capable of countering the phenomena of resistance linked to a lack of concentration of antibiotics within microorganisms (analogs of siderophores, inhibitors efflux pumps...).
The team's research themes revolve more specifically around 4 groups of infectious agents, found in clinical practice : 
1. ESKAPEE bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Actinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., Escherichia coli) - 2. Mycobacteria (typical and atypical) - 3. Plasmodium falciparum - 4. BK virus

A multidisciplinary approach

  • Epidemiological and clinical research studies (characterization of the biomolecular targets of epidemic strains),
  • Design and synthesis of new antibacterials, antimalarials and antivirals of a heterocyclic and/or peptide nature (siderophore analogues, antimicrobial peptides (AMP), arylamino alcohols, etc.),
  • Physicochemical evaluation and study of structure-activity relationships (SAR) in silico,
  • In vitro biological evaluation (efficacy, cytotoxicity, transmembrane passage) thanks to the development of cellular models and study of the mechanisms of action using biomolecular approaches (commercial or clinical strains, etc.),
  • Biological evaluation ex vivo and in vivo on animal models (efficacy, toxicity, pharmacokinetics, pharmacodynamics).